📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
56 announcements match the current filters (relevance ≥ 5).
JSLL to Engage with 25+ Institutional Investors at Nuvama 21st India Conference
Jeena Sikho Lifecare Limited (JSLL) has scheduled a series of group meetings with over 25 prominent institutional investors and asset management companies on February 10, 2026. The meetings will take place during the Nuvama 21st India Conference at Hotel Grand Hyatt, Mumbai. Participating entities include high-profile names such as PPFAS Mutual Fund, Motilal Oswal AMC, UTI Mutual Fund, and Aditya Birla Sun Life. These interactions are intended to discuss the company's business based on publicly available information, potentially increasing institutional visibility.
Key Highlights
Scheduled meetings with 25+ institutional investors and mutual funds on February 10, 2026.
Participation from top-tier funds including PPFAS Mutual Fund, Motilal Oswal AMC, and UTI Mutual Fund.
Four distinct group meeting slots scheduled between 10:00 AM and 1:50 PM.
Interaction organized as part of the Nuvama 21st India Conference in Mumbai.
👀 What to Watch
Investors should monitor for any post-conference analyst reports or increased institutional buying activity. The high level of interest from reputed funds suggests growing institutional confidence in the company's business model.
JSLL Reports One-Year Disease-Free Cancer Care Success in Peer-Reviewed Ayush Journal
Jeena Sikho Lifecare Limited (JSLL) has published a clinical case report in the 'Ayush Journal of Integrative Oncology' documenting a successful outcome for a 53-year-old breast cancer survivor. The report highlights a one-year disease-free resolution of recurrent lymphadenopathy achieved through the company's proprietary Ayurvedic protocols and lifestyle modifications. Co-authored by the Managing Director and the R&D team, this publication provides evidence-based validation for JSLL's clinical practices. This move is intended to strengthen the company's credibility in the integrative oncology space and support its research-driven growth strategy.
Key Highlights
Published case report in 'Ayush Journal of Integrative Oncology' documents a one-year disease-free status for a post-mastectomy patient.
Clinical resolution was documented via PET-CT scans, providing objective evidence for the efficacy of the Ayurvedic interventions.
The publication was co-authored by Managing Director Acharya Manish Grover and JSLL's Department of Research and Development.
Treatment involved a combination of personalized Ayurvedic formulations, Panchakarma therapies, and a 'Circadian D.I.P. diet'.
The report reflects the company's commitment to advancing Ayurvedic research and evidence-based clinical practices.
👀 What to Watch
Investors should view this as a positive step toward clinical validation of the company's treatments, which enhances brand trust and market positioning. Monitor for further R&D milestones that could drive long-term patient acquisition and revenue growth.
JSLL Approves AED 7.53 Million Unsecured Loan to International Subsidiary
Jeena Sikho Lifecare Limited (JSLL) has approved an unsecured loan of AED 7.53 million to its wholly-owned subsidiary, Jeena Sikho International LLC. The loan, to be disbursed in two tranches, carries an interest rate of 8.5% per annum with a tenure of five years to support the subsidiary's operational requirements. Separately, the company disclosed it has paid fines imposed by the NSE and BSE for past non-compliance with SEBI Regulation 29. This capital infusion suggests a focus on international expansion while the company works to strengthen its internal compliance systems.
Key Highlights
Approved an unsecured loan of AED 7.53 million to wholly-owned subsidiary Jeena Sikho International LLC
Loan features an interest rate of 8.5% per annum on a simple interest basis
The loan tenure is set for 5 years from the date of the first disbursement
Paid fines to NSE and BSE for non-compliance with Regulation 29 regarding board meeting intimations
Transaction is confirmed to be on an arm's length basis as a related party transaction
👀 What to Watch
Investors should monitor the growth and revenue contribution of the international subsidiary following this capital infusion. Additionally, keep a watch on the company's future regulatory filings to ensure compliance issues are fully resolved.
Jeena Sikho Lifecare to Acquire 51% Stake in UAE-based Back to Roots Ayurveda for AED 1.53 Million
Jeena Sikho Lifecare Limited (JSLL) has announced that its international subsidiary will acquire a 51% controlling stake in Abu Dhabi-based Back to Roots Ayurveda for AED 1.53 million. This acquisition marks a significant step in JSLL's global expansion strategy within the Ayurveda and wellness sector. The target entity has shown rapid growth, with turnover increasing from AED 0.77 million in 2024 to AED 2.5 million in 2025. The transaction is expected to be completed within 2-3 months via cash consideration, making it a step-down subsidiary of JSLL.
Key Highlights
Acquisition of 51% equity stake in Back to Roots Ayurveda by Dr. Shyam LLC for AED 1.53 million.
Target company turnover grew over 220% year-on-year, reaching AED 2.5 million in 2025 from AED 0.77 million in 2024.
The deal establishes a strategic international footprint for JSLL in the UAE's growing wellness and Panchakarma market.
The acquisition is a cash-only transaction expected to be finalized within approximately 2-3 months.
Back to Roots Ayurveda is a relatively new entity, incorporated in December 2023, showing high growth potential.
👀 What to Watch
Investors should look favorably on this international expansion as it diversifies revenue streams into a high-margin wellness market. Monitor the successful integration of the UAE operations and its impact on consolidated profitability in the next fiscal year.
Jeena Sikho Lifecare Partners with Theryco for Amazon E-commerce Distribution
Jeena Sikho Lifecare Limited (JSLL) has entered into a procurement agreement with Theryco Healthcare Solutions Private Limited to enhance its digital presence. Under this agreement, dated January 3, 2026, Theryco is authorized to list, manage, and sell JSLL's products on the Amazon e-commerce platform. This strategic move is intended to strengthen the company's distribution reach and improve product availability across digital channels. The company has confirmed that the transaction is on an arm's length basis and does not involve any related parties.
Key Highlights
Procurement agreement signed with Theryco Healthcare Solutions on January 3, 2026.
Theryco authorized to manage and sell JSLL products specifically on the Amazon platform.
Strategic focus on strengthening digital distribution and enhancing product availability.
Transaction confirmed as non-related party and executed on an arm's length basis.
👀 What to Watch
Investors should monitor the company's upcoming quarterly results to see if this digital expansion translates into higher sales volumes. This move indicates a positive shift towards modernizing distribution channels.
JSLL Publishes Research on Ayurvedic Diabetes Care; HbA1c Drops from 7.3% to 6.4%
Jeena Sikho Lifecare Limited (JSLL) has published two research articles in international journals validating its Ayurvedic treatment protocols for Type 2 Diabetes and Chronic Kidney Disease. A key case study highlighted a patient's HbA1c reduction from 7.3% to 6.4% and a significant recovery in pancreatic function, with fecal elastase increasing from 102 µg/g to 694 µg/g. The study also reported a 50% reduction in triglycerides, from 439 mg/dl to 220 mg/dl, and a decrease in total cholesterol from 217 mg/dl to 157 mg/dl. These publications support the company's commitment to evidence-based Ayurveda and clinical advancement.
Key Highlights
Published two research papers in the European Journal of Pharmaceutical and Medical Research and IJAR
Patient HbA1c levels decreased from 7.3% to 6.4% following Ayurvedic intervention
Fecal pancreatic elastase levels improved significantly from 102 µg/g to 694 µg/g
Triglycerides were reduced by 50%, falling from 439 mg/dl to 220 mg/dl
Research authored by JSLL's Managing Director and senior medical consultants
👀 What to Watch
This scientific validation enhances the company's clinical credibility and brand value in the competitive wellness sector. Long-term investors should monitor if such research leads to higher patient acquisition and revenue growth.
JSLL Sanganer Hospital Receives NABH Accreditation for Panchakarma Services
Jeena Sikho Lifecare Limited (JSLL) has successfully secured the National Accreditation Board for Hospitals & Healthcare Providers (NABH) certificate for its Sanganer Hospital in Rajasthan. The accreditation specifically covers Panchakarma services and is valid under certification number AH-2025-0412 until November 10, 2028. This certification validates the company's commitment to high standards of patient safety and quality healthcare delivery. Such accreditations are vital for healthcare providers to enhance brand reputation and facilitate empanelment with insurance providers.
Key Highlights
Received NABH Certificate of Accreditation for Sanganer Hospital located in Rajasthan.
The accreditation is specifically for Panchakarma services under certification number AH-2025-0412.
The certificate is valid for a multi-year period expiring on November 10, 2028.
Signifies adherence to nationally recognized standards for quality healthcare and operational excellence.
👀 What to Watch
Investors should view this as a positive operational milestone that strengthens the company's competitive position in the Ayurvedic healthcare sector. Monitor for potential improvements in patient footfall and insurance tie-ups following this accreditation.
Jeena Sikho Lifecare Publishes Research on Ayurvedic CKD Treatment; Creatinine Levels Drop to 5.17
Jeena Sikho Lifecare Limited (JSLL) has announced the publication of three academic case studies and reports in international journals focusing on Ayurvedic management of Chronic Kidney Disease (CKD). A key case study highlighted in the filing demonstrated significant clinical improvements in a 56-year-old patient, with serum urea dropping from 230.86 mg/dL to 117.39 mg/dL and creatinine reducing from 6.32 mg/dL to 5.17 mg/dL. The research validates the company's proprietary Ayurvedic formulations and specialized 'DIP' diet protocols. These publications are part of JSLL's strategy to establish evidence-based credibility for its clinical practices and hospital-based treatments.
Key Highlights
Published three academic papers in the International Journal of Ayurveda and Herbal Research and Journal of Applied Science and Education.
Clinical results showed a significant serum urea reduction of approximately 49% (from 230.86 mg/dL to 117.39 mg/dL).
Serum creatinine levels improved from 6.32 mg/dL to 5.17 mg/dL during the observed treatment period.
Fasting blood sugar levels normalized from 130 mg/dL to 90 mg/dL, indicating improved metabolic control.
Research was co-authored by Managing Director Manish Grover and a team of senior Ayurvedic consultants and medical professionals.
👀 What to Watch
Investors should view this as a positive step toward clinical validation of the company's Ayurvedic protocols, which could enhance brand trust and patient footfall. Monitor if this scientific validation leads to increased revenue in the hospital and wellness product segments.
JSLL Empanels 44 Ayurveda Hospitals with Medsave Health Insurance TPA for Cashless Treatment
Jeena Sikho Lifecare Limited (JSLL) has successfully empanelled 44 of its Ayurveda Panchkarma Hospitals with Medsave Health Insurance TPA Limited. This strategic arrangement enables the company to provide cashless Ayurvedic treatments to insured beneficiaries across a wide network of locations. The empanelment covers major Indian cities including Mumbai, Delhi, Bangalore, Hyderabad, and Kolkata, significantly enhancing service accessibility. This move is expected to drive higher patient footfall and revenue by integrating traditional treatments with mainstream insurance coverage.
Key Highlights
Empanelment of 44 Ayurveda Panchkarma Hospital locations across India with Medsave Health Insurance TPA.
Authorization to provide cashless treatment to insured beneficiaries under policies administered by Medsave.
Geographical footprint spans major hubs including Navi Mumbai, Bangalore, Ahmedabad, Pune, and Lucknow.
The arrangement is conducted in the ordinary course of business without any related party transactions.
👀 What to Watch
Investors should monitor the impact of this empanelment on patient volumes and revenue growth in the upcoming quarters as insurance-backed Ayurvedic care gains traction. This development strengthens the company's competitive position in the organized wellness and healthcare sector.
JSLL Empanels 44 Ayurveda Hospitals with Medsave Health Insurance TPA for Cashless Treatment
Jeena Sikho Lifecare Limited (JSLL) has announced the empanelment of its Ayurveda Panchkarma Hospitals with Medsave Health Insurance TPA Limited. This strategic move covers 44 hospital locations across India, enabling the company to provide cashless treatment to insured beneficiaries. By integrating with a major TPA, JSLL is likely to see an increase in patient footfall as Ayurvedic treatments become more accessible through insurance. This development aligns with the company's efforts to formalize and scale its healthcare service offerings across multiple states.
Key Highlights
Empanelment of 44 Ayurveda Panchkarma Hospital locations with Medsave Health Insurance TPA.
Enables cashless treatment for beneficiaries covered under Medsave-administered health policies.
Network spans across key cities including Mumbai, Delhi, Bangalore, Hyderabad, and Chennai.
The arrangement is in the ordinary course of business and involves no related party transactions.
Expected to drive higher patient volumes by making specialized Ayurvedic care more affordable.
👀 What to Watch
Investors should view this as a positive step toward increasing service accessibility and potential revenue growth. Monitor upcoming quarterly results for improvements in patient occupancy and average revenue per bed.
JSLL Empanels 44 Ayurveda Hospitals with Medsave TPA for Cashless Treatment
Jeena Sikho Lifecare Limited (JSLL) has announced the empanelment of 44 of its Ayurveda Panchkarma Hospitals with Medsave Health Insurance TPA Limited. This strategic move enables the company to provide cashless treatment to insured beneficiaries across a wide network of locations including major cities like Mumbai, Delhi, and Bangalore. By integrating with a TPA, JSLL is likely to see an increase in patient footfall from the insured segment, which has historically been a barrier for traditional Ayurvedic treatments. The empanelment is part of the company's ordinary course of business and aims to enhance service accessibility and revenue potential.
Key Highlights
Total of 44 hospital locations empanelled under the Medsave Health Insurance TPA network.
Enables cashless Ayurveda Panchkarma treatment for policyholders administered by Medsave TPA.
Network spans across multiple states including Maharashtra, Haryana, Uttar Pradesh, Rajasthan, and Karnataka.
The agreement is expected to drive higher utilization of hospital facilities and increase the addressable customer base.
👀 What to Watch
Investors should view this as a positive step towards mainstreaming Ayurvedic treatments and expanding the company's market reach. Monitor the impact on quarterly patient volumes and revenue growth as these cashless facilities become operational.
JSLL Empanels 44 Ayurveda Hospitals with Medsave Health Insurance TPA for Cashless Treatment
Jeena Sikho Lifecare Limited (JSLL) has announced the empanelment of 44 of its Ayurveda Panchkarma Hospitals with Medsave Health Insurance TPA Limited. This strategic partnership enables the company to offer cashless treatment to insured beneficiaries across a vast network of locations including Mumbai, Bangalore, Delhi, and Chennai. By integrating with a major TPA, JSLL is positioned to increase patient footfall and revenue from the insured demographic. The arrangement is conducted in the ordinary course of business and involves no related party transactions.
Key Highlights
Empanelment of 44 hospital locations across India with Medsave Health Insurance TPA Limited.
Enables cashless Ayurveda Panchkarma treatments for insured beneficiaries.
Network covers major Tier-1 and Tier-2 cities including Mumbai, Bangalore, Hyderabad, and Kolkata.
Strategic move to increase patient volumes by making treatments more accessible through insurance coverage.
👀 What to Watch
Investors should monitor the impact of this empanelment on the company's patient volume and revenue growth in upcoming quarters. This development strengthens JSLL's position in the organized wellness and Ayurvedic healthcare sector.
Jeena Sikho Lifecare Appoints Forvis Mazars LLP as Internal Auditor Following Resignation
Jeena Sikho Lifecare Limited (JSLL) has announced a change in its internal audit function effective December 23, 2025. The company accepted the resignation of M/s Deepak K Garg & Associates, who cited pre-occupation with other professional commitments as the reason for leaving. In their place, the Board has appointed M/s Forvis Mazars LLP, a leading international assurance and advisory firm, for the financial year 2025-26. This transition to a global firm is typically seen as a move to strengthen internal controls and corporate governance.
Key Highlights
Resignation of M/s Deepak K Garg & Associates as Internal Auditor effective December 23, 2025.
Appointment of M/s Forvis Mazars LLP as the new Internal Auditor for the FY 2025-26 period.
Outgoing auditor confirmed no material reasons for resignation other than professional commitments.
The Board meeting for approval was held on December 23, 2025, concluding within 15 minutes.
👀 What to Watch
Investors should view the appointment of a globally recognized audit firm as a positive step for transparency and governance. No immediate portfolio action is required based on this routine management change.
JSLL Publishes 6 Medical Case Studies Validating Ayurvedic Treatment for Chronic Kidney Disease
Jeena Sikho Lifecare Limited (JSLL) has announced the publication of six case studies in medical journals such as the Academia Journal of Medicine and Advances in Applied Biological Research. These studies, co-authored by the company's Managing Director and medical experts, provide clinical evidence for Ayurvedic and Panchakarma interventions in managing Chronic Kidney Disease (CKD) and Diabetes. One specific case study reported a significant reduction in a patient's serum creatinine from 6.4 mg/dL to 3.55 mg/dL and urea from 142 mg/dL to 55.88 mg/dL. This move aims to strengthen the company's clinical credibility and promote evidence-based traditional healing.
Key Highlights
Publication of 6 distinct case studies in peer-reviewed journals focusing on CKD and Diabetes management.
Clinical data showed a patient's serum creatinine dropped from 6.4 mg/dL to 3.55 mg/dL over the treatment and follow-up period.
Urea levels in the primary case study decreased from 142 mg/dL to 55.88 mg/dL, indicating significant renal function improvement.
The research was co-authored by MD Acharya Manish Grover and a team of 8 medical professionals associated with the company.
The studies highlight the integration of Panchakarma therapies, specific herbal formulations, and the 'DIP Diet' in clinical practice.
👀 What to Watch
Investors should view this as a positive step toward clinical validation of the company's core service offerings, which may drive higher patient trust and footfall. Monitor if this research leads to wider institutional acceptance or expansion of their hospital network.
JSLL receives in-principle approval for ESOP listing of 2,50,000 shares
Jeena Sikho Lifecare Limited (JSLL) has received in-principle approval from both NSE and BSE for listing up to 2,50,000 equity shares of ₹2 each under the 'Jeena Sikho Employees Stock Option Scheme, 2025'. This regulatory filing indicates the company's progress in implementing its ESOP program. The approvals are subject to the company fulfilling various listing conditions and regulatory requirements. Investors should note that this is an in-principle approval and the actual listing is contingent on further compliances.
Key Highlights
In-principle approval received for listing of up to 2,50,000 Equity Shares.
Each equity share has a face value of ₹2.
Approval granted under 'Jeena Sikho Employees Stock Option Scheme, 2025'.
Approval received from National Stock Exchange of India Limited (NSE) vide Ref: NSE/LIST/51687 dated December 9, 2025.
Approval received from BSE Limited vide Ref: DCS/ESOP/IP/RG/3955/2025-26 dated December 10, 2025.
👀 What to Watch
Investors should monitor JSLL's progress in fulfilling the listing conditions and keep an eye out for the actual listing date. This ESOP issuance could potentially dilute existing shareholders' equity, but the impact is likely to be minimal given the relatively small number of shares involved.
JSLL Clinical Success: HbA1c Drops from 9.3% to 6.4% in Peer-Reviewed Ayurvedic Case Study
Jeena Sikho Lifecare Limited (JSLL) has published three clinical case studies in the 'World Journal of Pharmaceutical and Life Sciences' to provide evidence-based validation for its Ayurvedic treatments. A primary study on Type 2 Diabetes showed a significant reduction in HbA1c from 9.3% to 6.4% and a drop in Random Blood Sugar from 265 mg/dL to 153 mg/dL. The publications, co-authored by the Managing Director and senior medical consultants, also cover treatments for Pancreatitis and Liver disorders. This move strengthens the company's scientific credibility in the alternative medicine space.
Key Highlights
Published 3 case studies in the peer-reviewed 'World Journal of Pharmaceutical and Life Sciences' covering Diabetes, Pancreatitis, and Liver disorders.
Diabetes case study reported a significant HbA1c reduction from 9.3% to 6.4% and average glucose drop from 220 mg/dL to 137 mg/dL.
Patient weight improved from 59 kg to 62.6 kg during the treatment period from September 2024 to April 2025.
Treatments utilized the company's proprietary 'DIP Diet' and personalized Ayurvedic protocols including Shodhana and Shamana.
Studies were co-authored by MD Acharya Manish Grover and a team of six medical professionals associated with the company.
👀 What to Watch
Investors should recognize this as a positive step toward institutionalizing Ayurvedic practices through clinical evidence, which can enhance brand trust and patient acquisition. Monitor for further large-scale clinical trials that could provide deeper scientific moats for the company's services.
